JP2026507086A - 新規な二重特異性融合タンパク質及びその用途 - Google Patents

新規な二重特異性融合タンパク質及びその用途

Info

Publication number
JP2026507086A
JP2026507086A JP2025549728A JP2025549728A JP2026507086A JP 2026507086 A JP2026507086 A JP 2026507086A JP 2025549728 A JP2025549728 A JP 2025549728A JP 2025549728 A JP2025549728 A JP 2025549728A JP 2026507086 A JP2026507086 A JP 2026507086A
Authority
JP
Japan
Prior art keywords
glp
fusion protein
bispecific fusion
diabetes
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025549728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026507086A5 (https=
Inventor
ソン，ヨンチョル
ヤン，サンイン
ノ，ジェイル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Slbigen Inc
Original Assignee
Slbigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Slbigen Inc filed Critical Slbigen Inc
Publication of JP2026507086A publication Critical patent/JP2026507086A/ja
Publication of JP2026507086A5 publication Critical patent/JP2026507086A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2025549728A 2023-06-22 2024-06-21 新規な二重特異性融合タンパク質及びその用途 Pending JP2026507086A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR2023008718 2023-06-22
KRPCT/KR2023/008718 2023-06-22
PCT/KR2024/008655 WO2024263005A1 (ko) 2023-06-22 2024-06-21 신규 이중 특이성 융합단백질 및 그의 용도

Publications (2)

Publication Number Publication Date
JP2026507086A true JP2026507086A (ja) 2026-02-27
JP2026507086A5 JP2026507086A5 (https=) 2026-03-31

Family

ID=93935935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025549728A Pending JP2026507086A (ja) 2023-06-22 2024-06-21 新規な二重特異性融合タンパク質及びその用途

Country Status (5)

Country Link
EP (1) EP4733314A1 (https=)
JP (1) JP2026507086A (https=)
CN (1) CN121358758A (https=)
AU (1) AU2024313859A1 (https=)
WO (1) WO2024263005A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070115947A (ko) * 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
ES2623925T3 (es) 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
KR101442254B1 (ko) 2008-02-22 2014-09-24 포항공과대학교 산학협력단 최적의 진핵 세포 발현 벡터의 개발
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
KR102349717B1 (ko) * 2020-03-12 2022-01-11 주식회사 에스엘메타젠 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
US20240368239A1 (en) * 2020-03-12 2024-11-07 Sl Metagen Novel bispecific protein and use thereof

Also Published As

Publication number Publication date
WO2024263005A1 (ko) 2024-12-26
CN121358758A (zh) 2026-01-16
AU2024313859A1 (en) 2026-01-15
EP4733314A1 (en) 2026-04-29

Similar Documents

Publication Publication Date Title
JP7014515B2 (ja) 持続型インスリンアナログ結合体及び持続型インスリン分泌ペプチド結合体を含む糖尿病治療用組成物
JP6006309B2 (ja) 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
JP6722175B2 (ja) 代謝障害を処置するための組成物及びその使用方法
KR101382593B1 (ko) 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN115304666B (zh) 一种治疗代谢疾病的胰高血糖素类似物
KR102692516B1 (ko) 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
CA2965560A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
TW201010729A (en) GIP-based mixed agonists for treatment of metabolic disorders and obesity
JP2018504111A (ja) ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途
JP7443315B2 (ja) アシル化オキシントモジュリンペプチド類似体
KR102826981B1 (ko) 신규 이중 특이성 단백질 및 그의 용도
CN101220088A (zh) 人胰高血糖素样肽-1类似物的融合蛋白及其应用
JP2024519950A (ja) Ｇｄｆ１５変異体及びｇｌｐ－１受容体作動薬を含む併用投与用組成物
KR20120116942A (ko) 폴리펩티드 접합체
JP2026507086A (ja) 新規な二重特異性融合タンパク質及びその用途
KR20090077935A (ko) 내당능 장애 관련 증상을 예방하거나 치료하기 위한 인간 ｅｐｏ 수용체 작용제, 조성물, 방법 및 용도
AU2024317572A1 (en) Antibody conjugates and fusion proteins
KR102349717B1 (ko) 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
WO2026037938A1 (en) Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor
WO2025247309A1 (zh) 融合蛋白分子及其应用
CA2950266C (en) Composition for treating diabetes, comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
WO2025247305A1 (zh) 融合蛋白分子及其应用
JP2025513345A (ja) 腸疾患の予防又は治療のためのＧＬＰ－２と、インスリン分泌ペプチド、ＴＮＦα抑制剤、又はその両方の併用療法
KR20210141406A (ko) 신규 재조합 융합단백질 및 그의 용도
WO2026067799A1 (zh) Glp-1受体和胰淀素受体的共激动剂

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20260323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421